Information Miransertib (ARQ 092) HCl is a novel, orally bioavailable and selectiveAKT pathwayinhibitor exhibiting a manageable safety profile among patients with advanced solid tumors. Targets Akt2 (Cell-free assay); Akt1 (Cell-free assay); Akt3 (Cell-free assay) 4.5 nM; 5 nM; 16 nM In vitro ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells. In vivo Short-term oral administration of ARQ 092 or hydroxyurea, a main therapy for sickle cell disease, diminishes heterotypic cell-cell interactions in venules of sickle cell disease mice challenged with TNF-α. ARQ 092 is well tolerated at a continuous daily dose of 60 mg or a dose of 600 mg when administered once a week, for several months. ARQ 092 is likely to inhibit the activity of all AKT isoforms in intravascular cells and thereby attenuates the process of thrombosis and inflammation in SCD patients. ARQ 092 is highly active in a subset of endometrial tumors that harbor PI3K pathway gene mutations. Cell Research(from reference) Cell lines：MDA-MB-453 cells; NCI-H1650 cells; KU-19-19 cells Concentrations：0, 0.012, 0.037, 0.11, 0.33, and 1 μM Incubation Time：2 h
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Miransertib hydrochloride
Dangerous GoodsCAS number：1313883-00-9 molecular formula：C27H25ClN6
overview
compound introduction
Specs
| Chinese alias | 盐酸米兰塞替布 | ||
| English alias | Miransertib3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl]-2-Pyridinamine hydrochloride | ARQ-092 hydrochloride | Miransertib (ARQ 092) HCl | Miransertib | ||
| CAS number | 1313883-00-9 | molecular formula | C27H25ClN6 |
| molecular weight | 468.98 g/mol | Exact mass | ≥99% |
| PSA | 95.600 Ų | logp | 4.98 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
Signal word：
Warning
Hazard Statement：
H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 H302: 吞食有害
Statement of Preventive Measures：
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛：用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出，取出隐形眼镜。继续冲洗。
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
